Myrbetriq
Product formulated to relieve overactive bladder symptoms and designed to support bladder control by relaxing the bladder muscle.
Strengths: 50mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Betmiga
- Therapeutic class
Beta-3 Adrenoceptor Agonist
- Pharmacological class
Beta-3 Adrenoceptor Agonist
- Contraindications
hypersensitivity; severe uncontrolled hypertension
- Minor side effects
tachycardia; urinary tract infection; nausea; headache
- Moderate side effects
hypertension; dyspepsia; constipation
- Dosage forms
Prolonged-release tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Astellas
- Onset Time
1–2 weeks
- Duration
24 hours
- Storage instructions
Store at room temperature, away from excessive heat and moisture.
- Drug interactions
metoprolol; digoxin; flecainide; propafenone
- Age restrictions
Not recommended for children or adolescents.
- Pregnancy and breastfeeding
Pregnancy: Avoid. Breastfeeding: Avoid.
Precautions and warnings
monitor blood pressure; use with caution in severe renal impairment; use with caution in hepatic impairment
Serious side effects
angioedema — requires immediate medical attention; urinary retention — requires immediate medical attention; atrial fibrillation — requires immediate medical attention
Patient summary
Product formulated to relieve overactive bladder symptoms and designed to support bladder control by relaxing the bladder muscle.
Mechanism of action
This medicine activates beta-3 adrenergic receptors in the bladder, which helps the bladder relax and increase its capacity to hold urine, preventing frequent contraction.
Myrbetriq
Product formulated to relieve overactive bladder symptoms and designed to support bladder control by relaxing the bladder muscle.
Editorial Notes
- Active ingredient(s): Mirabegron
- Listed indication(s): Overactive Bladder
Available option
- 30 tablets - 50 mg1058-50-mg-17974